8-KEarnings & ResultsOther EventsExhibits & Filings

QUEST DIAGNOSTICS INC 8-K Report, Financial Results (Feb 10, 2026)

Filed February 10, 2026For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) has filed an 8-K report on February 10, 2026, detailing its financial results for the fiscal year and fourth quarter ended December 31, 2025, and announcing significant capital return initiatives. While specific financial figures from the press release are not detailed in this extract, the filing indicates that the company is sharing its operational and financial performance with investors. This update is crucial for understanding the company's recent performance and outlook. The accompanying press releases, incorporated by reference, contain the detailed financial outcomes that investors should review for a comprehensive understanding. Beyond the financial results, Quest Diagnostics is demonstrating a strong commitment to shareholder returns. The Board of Directors has authorized an additional $1 billion for common stock repurchases, signaling confidence in the company's valuation and financial health. Furthermore, the quarterly dividend has been increased by 7.5% from $0.80 to $0.86 per share, effective for the dividend payable in April 2026. This enhanced return to shareholders, combined with the share repurchase program, suggests a positive financial trajectory and a focus on enhancing shareholder value.

Key Highlights

  • 1Quest Diagnostics reported its financial results for the quarter and full year ended December 31, 2025.
  • 2The company announced an additional $1 billion authorization for common stock repurchases.
  • 3The quarterly dividend per share has been increased by 7.5%, from $0.80 to $0.86.
  • 4The dividend increase is effective with the payment on April 20, 2026, for shareholders of record on April 6, 2026.
  • 5The filing incorporates by reference two press releases containing detailed financial results and capital return information.

Frequently Asked Questions

The 8-K filing indicates that Quest Diagnostics announced its financial results for the quarter and full year ended December 31, 2025. Detailed financial figures are available in the press release attached as Exhibit 99.1, which is incorporated by reference.

The Board of Directors has authorized an additional $1 billion for the repurchase of the Company's common stock as part of its ongoing common stock repurchase program.

The increased quarterly dividend of $0.86 per share (up from $0.80) will be effective with the dividend payable on April 20, 2026, to shareholders of record on April 6, 2026.

Detailed information is provided in the press releases filed as Exhibit 99.1 (financial results) and Exhibit 99.2 (dividend increase and share repurchase authorization), both dated February 10, 2026, and incorporated by reference into this 8-K filing.